0001415889-24-009019.txt : 20240322 0001415889-24-009019.hdr.sgml : 20240322 20240322194623 ACCESSION NUMBER: 0001415889-24-009019 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240320 FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ballal Rahul D. CENTRAL INDEX KEY: 0001805097 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39247 FILM NUMBER: 24776663 MAIL ADDRESS: STREET 1: 116 HUNTINGTON AVENUE STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Enliven Therapeutics, Inc. CENTRAL INDEX KEY: 0001672619 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-647-8519 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: IMARA Inc. DATE OF NAME CHANGE: 20160419 4 1 form4-03222024_110316.xml X0508 4 2024-03-20 0001672619 Enliven Therapeutics, Inc. ELVN 0001805097 Ballal Rahul D. C/O ENLIVEN THERAPEUTICS, INC. 6200 LOOKOUT ROAD BOULDER CO 80301 true false false false 1 Common Stock 2024-03-20 4 M 0 13278 5.52 A 35619 D Common Stock 2024-03-20 4 S 0 13278 19.1642 D 22341 D Stock Option (right to buy) 5.52 2024-03-20 4 M 0 13278 0 D 2032-01-27 Common Stock 13278 19571 D The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. The number of shares beneficially owned (i) reflects the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split") and (ii) has been adjusted following an internal review of the Reporting Person's holdings. This transaction was executed in multiple trades at prices ranging from $19.005 to $19.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter. /s/ Ben Hohl, by power of attorney 2024-03-22